After a two week baseline period patients were randomised to receive 4 mg nedocromil sodium or placebo four times daily for eight weeks, followed by eight weeks using the alternative treatment. Other asthma drugs were continued unchanged. Patients who changed their therapy (except inhaled bronchodilators) or reported an exacerbation of respiratory systems were withdrawn. Throughout the study patients recorded symptom severity (night-time asthma, morning tightness, daytime asthma and cough) using a 0-4 scale (0 = no symptons, 1 = mild, 2 = moderate, 3 = severe, or 4 = very severe), the highest of three measurements of peak expiratory flow using a mini-Wright peak flow meter (on waking, 16.00-18.00 hours, and on going to bed), and medication used on daily diary cards. Patients with a nocturnal symptom score > 20 (night-time asthma plus morning tightness) over seven consecutive baseline days entered the treatment period.
evening PEFR values improved slightlybut not significantly -compared with placebo. Patient and clinician opinions favoured nedocromil sodium treatment. Daytime asthma, daytime cough, and clinic assessment of asthma severity (secondary efficacy variables) were improved with nedocromil sodium treatment; daytime bronchodilator use and clinic pulmonary function were not. Conclusions -Nedocromil sodium was more effective than placebo in reducing nocturnal symptons ofastlhma andbronchodilator use in this group of patients. (Thorax 1994; 49:1225 -1227 Nocturnal symptons are a common problem for asthmatic patients, with more than one third of patients being woken every night. ' After a two week baseline period patients were randomised to receive 4 mg nedocromil sodium or placebo four times daily for eight weeks, followed by eight weeks using the alternative treatment. Other asthma drugs were continued unchanged. Patients who changed their therapy (except inhaled bronchodilators) or reported an exacerbation of respiratory systems were withdrawn. Throughout the study patients recorded symptom severity (night-time asthma, morning tightness, daytime asthma and cough) using a 0-4 scale (0 = no symptons, 1 = mild, 2 = moderate, 3 = severe, or 4 = very severe), the highest of three measurements of peak expiratory flow using a mini-Wright peak flow meter (on waking, 16.00-18.00 hours, and on going to bed), and medication used on daily diary cards. Patients with a nocturnal symptom score > 20 (night-time asthma plus morning tightness) over seven consecutive baseline days entered the treatment period.
At clinic visits (baseline and after four and eight weeks of treatment) diary cards were checked, asthma severity assessed (as above), the highest of three measurements of FEV, forced vital capacity (FVC), and PEFR recorded from spirometric measurements, and adverse events noted.
Patients and clinicians rated overall treatment efficacy (1 = very effective, 2 = moderately effective, 3 = slightly effective, 4 = no effect, or 5 = made condition worse) and decided at the end ofthe study which treatment period was more effective. Patients also selected their preferred treatment (first, second or neither). Ciancy, Keogan PEFR= peak expiratory flow rate; FEV, =forced expiratory volume in one second; FVC=forced ventilatory capacity.
tNegative differences for symptom scores and inhaled bronchodilator use, and positive differences for lung function indicate a greater improvement with nedocromil sodium treatment.
*p<0o05; **p<0-01; ***p<0-001 (all in favour of nedocromil sodium).
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